Business Wire

TSYS Renews Commercial Payments Agreement with Degussa Bank in Germany

13.7.2017 11:00 | Business Wire

Jaa

TSYS (NYSE: TSS) announced today that it has extended its commercial payments agreement with Degussa Bank in Germany. The multi-year agreement covers a broad range of products and services that TSYS will provide Degussa Bank’s corporate and business clients.

Degussa Bank offers a low cost, efficient solution for its commercial clients. TSYS provides processing services for the bank’s Mastercard® and Visa® products, as well as account decisioning and fraud and risk management services. A TSYS client since 2010, Degussa Bank chose TSYS for its market-leading technology, a proven delivery track record and its partnering approach.

“We are excited to extend our agreement with TSYS,” said Dieter Bourlauf, chief digital officer of Degussa Bank. “Their strong track record of success and stellar reputation in the commercial card industry, combined with the quality service we have experienced since our original conversion onto their platform, gives us confidence that they will continue to help our commercial card program grow and flourish.”

“It is a great feeling when a valued client like Degussa Bank renews their agreement with TSYS,” said Rob Hudson, group executive, TSYS International. “We established years ago that Germany was an important market to us, and with the Degussa Bank renewal and other recent renewals in the German market, TSYS proves how we can provide value in a number of different ways to German issuers.”

Terms of the long-term agreement were not released.

About Degussa Bank

Degussa Bank is Germany’s one and only WorksiteFinancial Services Bank with a focus on you as a professional. Our special feature is the proximity to your working environment - the Worksite. With us as a WorksiteBank, you can settle your bank business conveniently with one of our 200 partner companies on the company premises in the Bank-Shop, as well as by telephone, InternetBanking or smartphone app.

We are one of the largest providers of commercial cards in Germany and offer our customers comprehensive credit card-based solutions for travel management, travel expenses and procurement. Degussa Bank company cards are always a reliable companion for business travel.

As a customer of Degussa Bank, you have a competent partner for financial solutions. Always adapted to your wishes and possibilities, you profit from our complete range of financial and corporate services to special employee conditions - simple, transparent and fair.

About TSYS

TSYS® (NYSE: TSS) is a leading global payments provider, offering seamless, secure and innovative solutions across the payments spectrum — from issuer processing and merchant acquiring to prepaid program management. We succeed because we put people, and their needs, at the heart of every decision. It’s an approach we call ‘People-Centered Payments®’.

Our headquarters are located in Columbus, Ga., U.S.A., with approximately 11,500 team members and local offices spread across 13 countries. TSYS generated revenue of $4.2 billion in 2016, while processing more than 25.5 billion transactions. We are a member of The Civic 50 and were named one of the 2017 World’s Most Ethical Companies by Ethisphere magazine. TSYS is a member of the S&P 500 and routinely posts all important information on its website. For more, visit tsys.com.

Contact information

TSYS
Media Relations:
Cyle Mims, +1 706-644-3110
cylemims@tsys.com
or
Investor Relations:
Shawn Roberts, +1 706-644-6081
shawnroberts@tsys.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 21:33Tiedote

The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 15:09Tiedote

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 14:26Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s

NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 10:00Tiedote

NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve

Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 08:00Tiedote

Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme